Association between Bone Marrow Hypermetabolism on 18 F-Fluorodeoxyglucose Positron Emission Tomography and Response to Chemotherapy in Non-Small Cell Lung Cancer

Methods: We evaluated the patients with advanced NSCLC and who were treated with combination chemotherapy. For determination of the standardized uptake value (SUV) of the bone marrow (BM SUV) on FDG-PET, regions of interest (ROIs) were manually drawn over the lumbar vertebrae (L1, 2, 3). ROIs were also drawn on a homogenous transaxial slice of the liver to obtain the bone marrow/ liver SUV ratio (BM/L SUV ratio). The response to chemotherapy was evaluated according to the Response Evaluation Criteria in Solid Tumor (RECIST) criteria after three cycles of chemotherapy. Results: Fifty-nine NSCLC patients were included in the study. Multivariate analysis was performed using a logistic regression model. The BM SUV and the BM/L SUV ratio on FDG-PET were not associated with a response to chemotherapy in NSCLC patients (p=0.142 and 0.978, respectively). Conclusion: The bone marrow hypermetabolism seen on FDG-PET can not predict a response to chemotherapy in NSCLC patients.

[1]  J. Soh,et al.  ERCC1 protein expression predicts the response of cisplatin-based neoadjuvant chemotherapy in non-small-cell lung cancer. , 2008, Lung cancer.

[2]  D. Gandara,et al.  Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  T. Naruke,et al.  Prognostic significance of [18F]fluorodeoxyglucose uptake on positron emission tomography in patients with pathologic stage I lung adenocarcinoma , 2006, Cancer.

[4]  F. Hirsch,et al.  Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Y. Bang,et al.  High Fluorodeoxyglucose Uptake on Positron Emission Tomography in Patients with Advanced Non–Small Cell Lung Cancer on Platinum-Based Combination Chemotherapy , 2006, Clinical Cancer Research.

[6]  F. Bénard,et al.  Bone marrow hypermetabolism on 18F-FDG PET as a survival prognostic factor in non-small cell lung cancer. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[7]  R. Cerfolio,et al.  The maximum standardized uptake values on positron emission tomography of a non-small cell lung cancer predict stage, recurrence, and survival. , 2005, The Journal of thoracic and cardiovascular surgery.

[8]  K. Forster,et al.  [18F]fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  K. Feldmann,et al.  Circulating Nucleosomes Predict the Response to Chemotherapy in Patients with Advanced Non–Small Cell Lung Cancer , 2004, Clinical Cancer Research.

[10]  A. Argiris,et al.  Can current treatments for advanced non-small-cell lung cancer be improved? , 2004, JAMA.

[11]  J. Herndon,et al.  Comparison of whole-body FDG-PET to bone scan for detection of bone metastases in patients with a new diagnosis of lung cancer. , 2004, Lung cancer.

[12]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[13]  T. Shanafelt,et al.  Are chemotherapy response rates related to treatment-induced survival prolongations in patients with advanced cancer? , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  W. Oyen,et al.  FDG-PET in staging lung cancer: how does it change the algorithm? , 2004, Lung cancer.

[15]  Thomas J. Smith,et al.  American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  R. Jakesz,et al.  Expression of Cell Cycle Regulatory Proteins in Breast Carcinomas Before and After Preoperative Chemotherapy , 2003, Breast Cancer Research and Treatment.

[17]  M. J. van de Vijver,et al.  Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome , 2003, British Journal of Cancer.

[18]  P. Bunn.  Chemotherapy for advanced non-small-cell lung cancer: who, what, when, why? , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  M. Boers,et al.  Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial , 2002, The Lancet.

[20]  Jin-Hyuk Choi,et al.  Vascular endothelial growth factor in the serum of patients with non-small cell lung cancer: correlation with platelet and leukocyte counts. , 2001, Lung cancer.

[21]  B. Freidlin,et al.  Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  D K Owens,et al.  Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. , 2001, JAMA.

[23]  D. Wood,et al.  Lung cancer proliferation correlates with [F-18]fluorodeoxyglucose uptake by positron emission tomography. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[24]  H. Groen,et al.  Preoperative staging of non-small-cell lung cancer with positron-emission tomography. , 2000, The New England journal of medicine.

[25]  A. Lammertsma,et al.  Monitoring response to therapy in cancer using [18F]-2-fluoro-2-deoxy-d-glucose and positron emission tomography: an overview of different analytical methods , 2000, European Journal of Nuclear Medicine.

[26]  D. Ferrigno,et al.  Prognostic value of stage grouping and TNM descriptors in lung cancer. , 2000, Chest.

[27]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[28]  M Schwaiger,et al.  Reproducibility of metabolic measurements in malignant tumors using FDG PET. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[29]  P. Dupont,et al.  Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: An analysis of 125 cases. Leuven Lung Cancer Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  N. Saijo,et al.  Progressive disease rate as a surrogate endpoint of phase II trials for non-small-cell lung cancer. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[31]  M. Paesmans,et al.  Prognostic factors for response to chemotherapy containing platinum derivatives in patients with unresectable non-small cell lung cancer. (NSCLC). , 1996, Lung cancer.

[32]  A. Dowlati,et al.  Evaluation of the solitary pulmonary nodule by positron emission tomography imaging. , 1996, The European respiratory journal.

[33]  V J Lowe,et al.  Lung tumor growth correlates with glucose metabolism measured by fluoride-18 fluorodeoxyglucose positron emission tomography. , 1995, The Annals of thoracic surgery.

[34]  O. Brodin,et al.  Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials , 1995 .

[35]  H. Kimura,et al.  Establishment of large cell lung cancer cell lines secreting hematopoietic factors inducing leukocytosis and thrombocytosis. , 1992, Japanese journal of clinical oncology.

[36]  A. Jemal,et al.  Cancer Statistics, 2007 , 2007, CA: a cancer journal for clinicians.